205 related articles for article (PubMed ID: 32533100)
1. Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.
Yang Y; Wang C; Sun H; Jiang Z; Zhang Y; Pan Z
Cancer Gene Ther; 2021 Feb; 28(1-2):89-97. PubMed ID: 32533100
[TBL] [Abstract][Full Text] [Related]
2. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma.
Yang C; Qin S
Cancer Med; 2018 Sep; 7(9):4570-4583. PubMed ID: 30109780
[TBL] [Abstract][Full Text] [Related]
3. Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells.
Li X; Xu A; Li H; Zhang B; Cao B; Huang J
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1693-1701. PubMed ID: 29486282
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.
Wang H; Gao C; Li X; Chen F; Li G
Sci Rep; 2024 Mar; 14(1):7140. PubMed ID: 38532022
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
[TBL] [Abstract][Full Text] [Related]
6. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging.
Liang Q; Kong L; Du Y; Zhu X; Tian J
Exp Mol Med; 2019 Jul; 51(7):1-11. PubMed ID: 31285418
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Wang Y; Li H; Liang Q; Liu B; Mei X; Ma Y
Tumour Biol; 2015 Mar; 36(3):1561-6. PubMed ID: 25371070
[TBL] [Abstract][Full Text] [Related]
8. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.
Chen H; Jiang T; Lin F; Guan H; Zheng J; Liu Q; Du B; Huang Y; Lin X
Int Immunopharmacol; 2021 Oct; 99():107929. PubMed ID: 34343940
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
10. Significant Efficacy of Apatinib in a Patient With Hepatocellular Carcinoma Lung Metastases After Liver Transplantation: A Case Report.
Yu Z; Liu W; Deng Y; Yao J; Tang H; Li H; Yang Y; Wang G; Chen G
Transplant Proc; 2018 Dec; 50(10):4042-4045. PubMed ID: 30577311
[TBL] [Abstract][Full Text] [Related]
11. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer.
Zhao S; Ren S; Jiang T; Zhu B; Li X; Zhao C; Jia Y; Shi J; Zhang L; Liu X; Qiao M; Chen X; Su C; Yu H; Zhou C; Zhang J; Camidge DR; Hirsch FR
Cancer Immunol Res; 2019 Apr; 7(4):630-643. PubMed ID: 30755403
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
14. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials.
Liang L; Wen Y; Hu R; Wang L; Xia Y; Hu C; Qiao Y; Geng X; Chen T; Fei J; Hui K; Jiang X
Cancer Immunol Immunother; 2019 Sep; 68(9):1467-1477. PubMed ID: 31451841
[TBL] [Abstract][Full Text] [Related]
17. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
19. IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma.
Wu Y; Cheng G; Chen H; Wang J; Wang J; Wang W
Clin Hemorheol Microcirc; 2021; 77(1):37-47. PubMed ID: 32651310
[TBL] [Abstract][Full Text] [Related]
20. Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Kou P; Zhang Y; Shao W; Zhu H; Zhang J; Wang H; Kong L; Yu J
Oncotarget; 2017 Mar; 8(12):20510-20515. PubMed ID: 28103584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
